Natera, Inc. is a pharmaceutical company based in the United States of America specializing in diagnostics and research. With an ESG risk rating score of 29.7, the company is considered to have a medium risk level. Natera's proprietary molecular and bioinformatics technology offers key product offerings such as the Panorama Non-Invasive Prenatal Test (NIPT) for screening chromosomal abnormalities in fetuses, Horizon Carrier Screening (HCS) for determining carrier status of genetic diseases, Signatera molecular residual disease (MRD) test for detecting circulating tumor DNA in cancer patients, and Prospera for assessing organ transplant rejection.